ARS Pharmaceuticals (SPRY) Other Non Operating Income (2022 - 2026)

ARS Pharmaceuticals has disclosed Other Non Operating Income across 5 years of filings, most recently posting $2.0 million for Q1 2026.

• Other Non Operating Income for Q1 2026 came in at $2.0 million, down 39.2% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.8 million (down 41.9% YoY), and the FY2025 annual result was $8.1 million, down 29.02% from the prior year.
• Other Non Operating Income came in at $2.0 million for Q1 2026 at ARS Pharmaceuticals, up from $61000.0 in the prior quarter.
• In the past five years, Other Non Operating Income ranged from a high of $3.8 million in Q1 2023 to a low of -$151000.0 in Q1 2022.
• The 5-year median for Other Non Operating Income is $2.7 million (2025), against an average of $2.1 million.
• Across the five-year window, Other Non Operating Income soared 6521.28% in 2023 and tumbled 97.98% in 2025, its largest moves.
• ARS Pharmaceuticals' Other Non Operating Income stood at $1.2 million in 2022, then surged by 164.99% to $3.1 million in 2023, then fell by 1.08% to $3.0 million in 2024, then sank by 97.98% to $61000.0 in 2025, then soared by 3126.23% to $2.0 million in 2026.
• The last three Other Non Operating Income figures came in at $2.0 million (Q1 2026), $61000.0 (Q4 2025), and $2.0 million (Q3 2025), per Business Quant data.